hVIVO preps phase 3 for ‘universal’ flu vaccine
U.K. biotech hVIVO is on course to start a phase 3 program for a flu vaccine that doesn’t need to have its composition tweaked every year—and as a result has been tipped by some analysts as a potential blockbuster.